OSE Immunotherapeutics SA/€OSE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About OSE Immunotherapeutics SA
OSE Immunotherapeutics SA is a biotechnology company focused on the research and development of immunotherapies in the fields of immune-oncology, autoimmune diseases, and transplantation. The company aims to innovate through its pipeline, which includes products such as Tedopi, a therapeutic vaccine for non-small cell lung cancer, and CoVepiT, a COVID-19 vaccine. Founded in 2012 and headquartered in Nantes, France, OSE Immunotherapeutics combines strong scientific expertise with a strategic emphasis on building a diversified portfolio of advanced clinical trials. The company's competitive strength lies in its proprietary technologies and strategic partnerships, enhancing its capabilities to address significant unmet medical needs globally.
- Ticker
- €OSE
- Sector
- Health
- Primary listing
- PAR
- Employees
- 64
- Headquarters
- Nantes, France
- Website
- www.ose-immuno.com
OSE Metrics
BasicAdvanced
€41M
-
-€1.69
0.89
-
Price and volume
Market cap
€41M
Beta
0.89
52-week high
€6.17
52-week low
€1.67
Average daily volume
166K
Financial strength
Current ratio
1.285
Quick ratio
1.191
Long term debt to equity
0.888
Total debt to equity
1.308
Interest coverage (TTM)
-13.29%
Profitability
EBITDA (TTM)
-29.468
Gross margin (TTM)
88.70%
Net profit margin (TTM)
-1,824.86%
Operating margin (TTM)
-1,721.44%
Effective tax rate (TTM)
-0.74%
Revenue per employee (TTM)
€30,000
Management effectiveness
Return on assets (TTM)
-18.42%
Return on equity (TTM)
-66.82%
Valuation
Price to revenue (TTM)
21.426
Price to book
1.14
Price to tangible book (TTM)
1.4
Price to free cash flow (TTM)
-1.411
Free cash flow yield (TTM)
-70.85%
Free cash flow per share (TTM)
-1.23
Growth
Revenue change (TTM)
-96.77%
Earnings per share change (TTM)
-215.82%
3-year revenue growth (CAGR)
-54.00%
10-year revenue growth (CAGR)
91.77%
3-year earnings per share growth (CAGR)
20.77%
10-year earnings per share growth (CAGR)
11.10%
What the Analysts think about OSE
Analyst ratings (Buy, Hold, Sell) for OSE Immunotherapeutics SA stock.
Analyst projections of the future price of OSE Immunotherapeutics SA stock.
OSE Financial Performance
Revenues and expenses
OSE Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.